We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Integumen Plc | SKIN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 28.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 28.00 | 28.00 |
| Top Posts |
|---|
Posted at 05/10/2020 09:56 by monkey puzzle Hi John,TA won't be much use here I'm afraid. Skin is being shorted to death which brings out sellers as well and despite some good buying volumes, MMs seem interested in only moving the share price one way. Still waiting to see what further SKIN/MWG contracts are coming via the water monitoring side and the Labskin clients. |
Posted at 01/10/2020 11:30 by monkey puzzle hxxp://www.global-enCombining the Labskin lab-grown 3D skin models and Labskin’s ability to harvest and replicate the skin microbiome of a human volunteer, the Remote Clinical Trial platform is an innovative, problem-solving platform which guarantees accurate, socially-distanced product-testing capabilities for cosmetics and skin care brands. During the webinar Paul Ryan and Alex Chapman will take you through the Labskin laboratory facility in the UK with a virtual tour, followed by an in-depth presentation of the Remote Clinical Trial platform and a case study that will guide you through the Remote Clinical Trial journey from a client perspective. A live and moderated Q&A session will close out the webinar, and questions can be directed here. Date: 20 October 2020 Time: New York – 11:00 | London – 16:00 | Paris – 17:00 | Singapore – 23:00 |Tokyo – 00: 00 (21 October) |Sydney – 01:00 (21 October) Duration: 75 minutes Event structure: Virtual lab tour, 2 presentations and Q&A Registration fee: Complimentary access Webinar on-demand: Available to view until midnight 4 November 2020 (registration is required) Labskin’s pioneering approach to testing skin care products by cloning a patient’s skin microbiome and transplanting it on to Labskin human skin equivalent allows a wide range of testing that no longer requires invasive procedures on patients. Data from next generation sequencing of the Labskin and skin biome is coupled with AI processes to interpret and direct further development of skincare products in a controlled and efficient manner, reducing development time and costs. |
Posted at 01/10/2020 07:21 by monkey puzzle RE: A re-imagined look at skin model testing – Q&A with LabskinWed 23:172/2 China still mandates that cosmetics safety has to be tested in animals although recent announcements have lifted restrictions on importing cosmetic products with alternative methods for safety assessment. The Chinese regulator is looking to establish alternatives in vitro standards to animal testing. Labskin is in an excellent position to become a key part of the new regulatory environment emerging in the Chinese cosmetics market. In January 2020 Labskin signed a Memorandum of Understanding with the Innocare Group to promote innovation and cooperation on regulatory compliance without animal testing. To make our skin models more relevant to Asian markets, Labskin is collaborating with the University of Bradford to develop a model containing melanocytes so that next-generation skin models can be created using cells from donors with different ethnic backgrounds. Melanin is a natural sink of chemical compounds so different level of pigmentation could become an important factor not only for safety testing and efficacy. Looking ahead 10 or 20 years from now, what does the future hold for the lab–grown human skin model? How far can you go? At this point, there is no limit to what we can do with skin models. The most urgent matter to address is adding extra complexity. This includes the need for melanocytes and Langerhans cells, sourced to improve the immune response of the models. Research demonstrates that this is possible; it just needs to be commercially produced. The next step will be to add complex macrostructures, such as hair follicles, sweat and sebaceous glands, possibly by reprogramming stem cells. Blood vessels could be developed inside a 3D model like Labskin as we know that seeding endothelial cells into a skin model produces a self-organized microvasculature. A combination of these techniques and 3D bioprinting will give rise to a new generation of skin models with blood/lymphatic vessels that could be connected to a microfluidic system, similar to our circulatory system, wired to keep the skin alive. All of this improvement combined with further developments in acute, chronic toxicology and efficacy will result in improved models. hxxps://connect.in-c ReplyRecommend (5)Report Post E_AL Premium Member Posts: 2,950 Price: 34.75 No Opinion A re-imagined look at skin model testing – Q&A with LabskinWed 23:16 1SEPTEMBER 29, 2020 1/2 * An interview with David Caballero-Lima, R&D Manager, Labskin Labskin has been around for twelve years – can you tell us about the history of the company as well as your field of expertise? The Labskin model was created by a group of microbiologists at the University of Leeds to study the skin human microbiota and the microbial/host interaction in a controlled environment. Labskin has unique features, including its improved barrier function, dry surface and the expression of antimicrobial peptides which allow the colonization of the model with skin microbiome. We use these defining characteristics to develop methods for testing ingredients and formulations on the microbial community on Labskin. We colonise Labskin with different microbial consortia containing mixes of skin bacteria and fungi. We can also isolate the whole microbiome from volunteers and transplant this microbiome onto Labskin. We can even challenge those consortia or microbiomes with pathogens. Then, combining a range of techniques such as colony counting, RT-qPCR, immunohistochemistry We can’t avoid the obligatory question about Covid-19 and testing sanitizers… you collaborate with various universities and academics…any exciting initiatives you can share with us? We regularly carry out tests on skin sanitisers, soaps and cleansers using our commensal skin consortia and specific pathogens. In the lab, our standard methods for testing sanitisers against the virus implement the most robust safety measures. We are now working with two leading universities with Containment Level 3 biosafety levels for specific laboratory work on SARS–CoV2. Most data on the efficacy of hand sanitisers against the Covid-19 virus do not correlate to a real-life situation. We use our Labskin model to get data in an environment that closely resembles real human skin. Additionally, we isolate microbiome from volunteers and have developed methods to isolate those microbiomes without contact with the subject. In effect, we run remote clinical trials that use an internet portal to recruit and send swabs to the volunteers and recover the whole microbiomes from those volunteers to safely transplant them onto our skin models in our facilities. |
Posted at 29/9/2020 13:59 by homeboy indeed, as said already -"this market keeps shifting by the week and skin is already behind the curve, breath testing on a disposable device is already here, skin's offering needs expensive additional support equipment and there's no clarity about who is going to be actually buying that, stand alone disposable is the way forward, and that aint skin, it's already a dud" the underlying non covid business doesn't seem to get any mention these days, maybe the big cosmetic players are cutting testing due to collapse in their own sales wouldn't bank on anything here being great value, it's become an r&d outfit with all the risk and uncertainty that goes with it i'd ignore all these cut and paste fools, they're just desperate to ramp the price up, most have cashed in here, that's why you're not seeing hundreds of barking mad posts everyday now |
Posted at 29/9/2020 08:44 by homeboy next year in this game is a lifetime away, by the time they actually manage to commercially produce their test kit - not forgetting they require very expensive machines installed on a substantial footprint - ten other players will have entered the market,this market keeps shifting by the week and skin is already behind the curve, breath testing on a disposable device is already here, skin's offering needs expensive additional support equipment and there's no clarity about who is going to be actually buying that, stand alone disposable is the way forward, and that aint skin, it's already a dud all in my highly experienced opinion |
Posted at 26/9/2020 10:46 by tickboo Lunsam on lse-To clear up a couple of points, the share price did not halve because of the AGM, the share price halved because Helium sold 6% of Integumen, pretty much in one go. Traders had already bought in the morning, and so when there were 6 million shares on the bid there was simply not enough demand to take them. Obviously this means they walk down the buy price until someone does buy them. GB had built it up on Twitter, and so had attracted a lot of traders in the prior days, the news was irrelevant to them. These guys who trade for gains of 10-20% in a few days were now down 10-20%, this clearly creates panic and adds to the number of shares being sold. IF there had been no hype on social media platforms, the share price would likely have been at 30p when the BT was announced, it likely would have gone to 70 on the news and Helium would have still sold 6%, taking the price back down. I doubt we would be back down to where we are now, but Helium selling is totally unforeseen and out of Gerrys control. Combined SKIN and MWG (at 65p) represented over 40% of Heliums Portfolio, any decent investors on this board know that that is overexposure to a single company. Per the last disclosure, they own 3.32% of SKIN and 13.55% of MWG. This is c. 8% of the enlarged entity. GB will now realise that what he did on Twitter was partially responsible for the capitulation, he is a large shareholder and so as he said himself, will have noticed. He also doesn't really care for daily share price movements, he is trying to build a large company and will look at this on a 3 year time horizon (or something like that anyway). Genuine excitement got misconstrued, and i would be very surprised to see more minions on Twitter 8 hours before a significant announcement. The fundamentals do remain unchanged, he has grown revenues 400% year on year and is looking at that same multiple this year. Revenue guidance for this half year suggests that we will be on the cusp of EBITDA positive. We have £1m of exercised warrants in the bank, and a £3m debt facility. That is plenty to see the final development of both the above ground, and below ground waste-water test through. They have access to one of the 7 (i think) Category 3 Laboratories in Aberdeen, that is not easy to get access to. He will be in contact with Cruise companies, Airlines, Schools etc. This is the perfect solution for them. He is in contact with multiple Governments (he has no reason to lie about this).Investors (maybe not traders), should look past Covid, and realise how transferable the technology is that is being built. What you can do for one disease, you can do for many others. This is so far from a one trick pony that many on this board seem to think it is. I have total faith that DeepVerge (SKIN + MWG) will be a market leading ESG investment within the Skincare and Water Industry over years to come. |
Posted at 25/9/2020 17:03 by montynj Below is copy and paste from lunsam on Twitter...v useful "Yesterday was a perfect storm. Day-traders looking for the next 'Covid moonshoot', coupled with their a major shareholder, the Helium Rising Stars Fund, selling nearly 6%. Helium only invest to £50m mcap, at 61p/64p where they sold #SKIN + #MWG had a combined mcap of >£100m. Its not within the fund investment strategy to hold companies of that size, which is why they sold. Its a shame it happened yesterday, it created utter panic amongst PIs and what can be only seen as the most ridiculous day of share price movement I have ever seen on AIM. 3/15I see significant value in the 4 core business channels;1. #Labskin - lab-grown human skin, enables remote clinical trials of skincare products, prevents the need of animal testing of skin products. 2. #Rinocloud - artificial intelligence, data management, machine learning 4/153. Water Monitoring - once #MWG is acquired, #DVRG have access to Gold-Standard water monitoring kit, and a worldwide distribution channel.4. Covid Monitoring - below ground and above ground, waste-water community screening, and above ground breath-testing. 5/15These are 4, potentially industry-revolutioni |
Posted at 24/9/2020 08:36 by thetrotsky I don't think the share price disparity between SKIN and MWG is helping matters; I wouldn't be surprised if some SKIN shareholders are still selling to buy MWG. If you can sell SKIN at (say) 65p and buy MWG at (say) 60p, why not? But it helps blunt any upward momentum in the SKIN price and an at one point this morning the MWG share price actually got ahead of SKIN! The MMs are loving it! |
Posted at 24/9/2020 05:55 by hamidahamida Who do you guys think is this 1 global major working with skin.......#SKIN #DVRG #MWG #Avacta #AptamerGroup #CIT #ecowaterOS #Cellulac #acumen #Tyndall #Rinocloud #UniAberdeen #CappaPhotonics @Labskin #tcbbResource plus one major global... Oh wait... you will have to watch the AGM. investormeetcompany. |
Posted at 22/9/2020 11:02 by turvart Monkey Puzzle,From what I can make out with my experience is that MWG was offered 4.05p at the last closing price of the takeover announcement, this will then give MWG 34% of DVRG but 1 share of MWG will equal 1 share of DVRG, meaning that MWG is merged with Skin in a new company, but because SKIN had more shares than MWG then skin holds a higher percentage in the merger. What I'm trying to say is that Skin & MWG are equal in price after the merger but because skin has more shares then skin is the larger part of the merger but they are both equal in share price with regards the merger. PS: I forgot to add that when MWG gets merged into DVRG that 10 shares will become 1 share but the share price will rise 10 fold. I hope this clears any confusion. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
